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ABSTRACT: Molecularly targeted therapy is guided by an
understanding of relevant genetic variations among individuals
with a particular disease and, when applicable, by the relevant
molecular variations in the expression of that disease. This
approach has the potential to discriminate potential responders
from nonresponders, identify which patients are likely to bene-
fit earlier in the disease pathway, ensure appropriate dosing,
reduce incidence of adverse events, and improve overall health
gain. Stated otherwise, molecularly targeted therapy maximises
the number of appropriately treated patients while minimising
the number exposed to the treatment but in whom it ulti-
mately fails. The benefits, however, must be balanced against
the cost of screening tests to identify who is most likely to ben-
efit from targeted therapy and against the lifetime costs of
treatment.
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It is obvious that the status of pharmacoeconomics is now at a
critical point. The challenge to health care payors is that they
are confronted by the basic economic principle of resource scar-
city and infinite demands. Health care resources are limited and
pressure is increasing to contain the growth of overall health care
costs. Demand is driven by a combination of demographic
change, patient knowledge and new technologies. Patient
demand fuels the search for new technologies and increases
pressure on the reimbursement systems.
Consequently, economic theory is increasingly being applied
in health care decisions, specifically in regard to coverage for
new technologies. Currently, a large proportion of lifetime health
care expenditures occur at the end of life. Targeted therapies can
shift the economics from excessive end-of-life spending to
investing in prevention, earlier diagnosis, and early treatment of
chronic conditions, Fig. 1. The early stages of developing molecu-
larly targeted agents are likely to entail substantial investments
in diagnostics and prevention, but savings might accrue during
the later stages when diseases are prevented and/or treatments
are applied with greater efficiency.1
HEALTH TECHNOLOGY ASSESSMENT: Health technology
assessment (HTA) is a multidisciplinary process that summarises
information about the medical, social, economic and ethical con-
cerns related to the use of a health technology in a systematic,
transparent, unbiased and robust manner. Its aim is to inform
safe and effective health policies that are patient focused and
seek to achieve best value.2
Payors, whether they are governments or insurance compa-
nies, must be accountable to the taxpayers or policyholders
whowant to know that their contributions are used in an efficient
manner. However, even the most robust HTA is subject to uncer-
tainty from several sources, for example, the relationship
between surrogate endpoints and final outcomes, the relation-
ship between efficacy and effectiveness and resource use distri-
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Fig. 1 – Savings from use of molecularly targeted agents
could be invested in diagnostics development and cancer
prevention.
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